Literature DB >> 26763598

The management of dry eye.

.   

Abstract

Dry eye disease (also called keratoconjunctivitis sicca) is a common condition, with a prevalence ranging from 8-34%, depending on the criteria used.(1) It becomes more common with increasing age and affects more women than men. Artificial tears and ocular lubricants are considered the mainstay of treatment and there is a very wide range of these products available. In England in 2014, over 6.4 million prescription items for artificial tears, ocular lubricants and astringents were dispensed in the community at a cost to the NHS of over £27 million.(2) In this article we review the management of dry eye disease, focusing on artificial tears and ocular lubricants. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26763598     DOI: 10.1136/dtb.2016.1.0378

Source DB:  PubMed          Journal:  Drug Ther Bull        ISSN: 0012-6543


  2 in total

Review 1.  Topical corticosteroids for dry eye.

Authors:  Su-Hsun Liu; Ian J Saldanha; Alison G Abraham; Thanitsara Rittiphairoj; Scott Hauswirth; Darren Gregory; Cristos Ifantides; Tianjing Li
Journal:  Cochrane Database Syst Rev       Date:  2022-10-21

2.  Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey.

Authors:  Parwez Hossain; Csaba Siffel; Corey Joseph; Juliette Meunier; Jessica T Markowitz; Reza Dana
Journal:  BMJ Open       Date:  2021-03-04       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.